Evidence map›Paper›PMID 39390132›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

Fluorescence detection of pituitary neuroendocrine tumour during endoscopic transsphenoidal surgery using bevacizumab-800CW: a non-randomised, non-blinded, single centre feasibility and dose finding trial [DEPARTURE trial].

I Schmidt, R A Vergeer, M R Postma, G van den Berg, A J Sterkenburg, A G W Korsten-Meijer, R A Feijen, S Kruijff, A P van Beek, W F A den Dunnen and 4 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04212793 (Detection of Pituitary Neuroendocrine Tumor), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04212793 phase1completednot on this map

Detection of Pituitary Neuroendocrine Tumor (PitNET) Tissue During Endoscopic Transsphenoidal Surgery Using Bevacizumab-800CW

TypeinterventionalSponsorUniversity Medical Center GroningenRan2020 to 2022Enrolled20ConditionsPituitary Tumor, Pituitary Adenoma, Pituitary MacroadenomaArmsBevacizumab-IRDye800CW, Molecular Fluorescence Endoscopy platform
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Imaging the hallmarks of cancer.Nature reviews. Cancer · 2026
    Review
  2. Pituitary adenoma imaging as a determinant of acromegaly diagnosis and outcomes.The Journal of clinical endocrinology and metabolism · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

I Schmidt *Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
R A Vergeer *Department of Neurosurgery, University of Groningen, University Medical Center Groningen, P.O. Box 30.001 (AB-71), Groningen, 9700 RB, The Netherlands. ra.vergeer@umcg.nl.ORCID 0000-0002-6700-196X
M R PostmaDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
G van den BergDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
A J SterkenburgDepartment of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
A G W Korsten-MeijerDepartment of Otorhinolaryngology- Head and Neck Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
R A FeijenDepartment of Otorhinolaryngology- Head and Neck Surgery, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
S KruijffDepartment of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
A P van BeekDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
W F A den DunnenDepartment of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
D J RobinsonCenter for Optical Diagnostics and Therapy, Department of Otorhinolaryngology- Head and Neck Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
J M C van DijkDepartment of Neurosurgery, University of Groningen, University Medical Center Groningen, P.O. Box 30.001 (AB-71), Groningen, 9700 RB, The Netherlands.
W B NagengastDepartment of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
J M A KuijlenDepartment of Neurosurgery, University of Groningen, University Medical Center Groningen, P.O. Box 30.001 (AB-71), Groningen, 9700 RB, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAchieving endocrine remission by gross total resection is challenging in pituitary neuroendocrine tumours (PitNETs) with cavernous sinus invasion. This study aims to assess the safety, feasibility, and optimal dose for intraoperative fluorescence imaging as an added instrument to discriminate PitNET from surrounding tissue using bevacizumab-800CW, targeting vascular endothelial growth factor A (VEGF-A).

methodsIn part I, dose-escalation (0-4∙5-10-25 mg) was performed in 4 groups of 3 patients with PitNETs Knosp grade 3-4. In part II, after interim analysis, the 10 mg and 25 mg groups were expanded to a total of 6 patients. Quantitative fluoroscence molecular endoscopy consisted of wide field fluorescence molecular endoscopy and multi-diameter single fiber reflectance / single fiber fluorescence spectroscopy. Mean fluorescence intensity (MFI) of the fresh surgical specimen was calculated and VEGF-staining was performed.

resultsEighteen patients were included. All doses were well tolerated. Three serious adverse events were registered, but none were tracer-related. Part I showed an adequate in-vivo tumour-to-background ratio for both 10 mg (TBR 2∙00 [1∙86, 2∙19]) and 25 mg (TBR 2∙10, [1∙86, 2∙58]). Part II revealed a substantially higher MFI in the 25 mg group. With both 10 mg and 25 mg a statistically significant difference between tumour and surrounding tissue was detected (p < 0∙0001). All surgical specimens had VEGF-A expression.

conclusionThis study demonstrates the safety and feasibility of quantitative fluorescence molecular endoscopy during PitNET surgery. Both 10 mg and 25 mg bevacizumab-800CW result in clear differentiation in-vivo, with improved contrast ex-vivo (MFI) in the 25 mg group.

trial registrationNCT04212793 / Study Details| Detection of PitNET Tissue During TSS Using Bevacizumab800CW| ClinicalTrials.gov.

Indexed as

BevacizumabEndoscopyNeuroendocrine TumorsOptical ImagingPituitary NeoplasmsAdultAgedDose-Response Relationship, DrugFeasibility StudiesFemaleHumansMaleMiddle AgedBevacizumabBevacizumabPituitary neuroendocrine tumorQuantitative fluorescence molecular endoscopyTranssfenoidal surgery

Identifiers

PMID39390132
PMCPMC11732902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.